Collegium Pharmaceutical (COLL) Financials

$29.18 +0.27 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$29.20 +0.02 (+0.07%)

As of 04:27 PM Eastern

Annual Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	69	48	-25	72	27	-23	-39	-75	-94	-27	0.00
Consolidated Net Income / (Loss)	69	48	-25	72	27	-23	-39	-75	-94	-27	0.00
Net Income / (Loss) Continuing Operations	69	48	-25	72	27	-23	-39	-75	-94	-27	0.00
Total Pre-Tax Income	99	76	-29	-3.37	28	-23	-39	-75	-94	-27	0.00
Total Operating Income	170	167	33	18	56	-24	-21	-75	-94	-27	0.00
Total Gross Profit	377	326	209	151	180	103	115	26	1.50	0.00	0.00
Total Revenue	631	567	464	277	310	297	280	28	1.71	0.00	0.00
Operating Revenue	631	567	464	277	310	297	280	28	1.71	0.00	-
Total Cost of Revenue	254	241	254	126	130	194	166	2.60	0.21	0.00	0.00
Operating Cost of Revenue	254	241	254	126	130	194	166	2.60	0.21	0.00	-
Total Operating Expenses	207	159	176	133	124	127	135	101	96	27	0.00
Selling, General & Admin Expense	210	159	172	119	114	116	127	93	81	19	-
Research & Development Expense	0.00	0.00	3.98	9.45	9.77	10	8.66	8.57	15	7.98	-
Other Special Charges / (Income)	-2.91	0.00	0.00	-	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	-71	-91	-62	-21	-29	1.03	-18	0.58	-0.09	-0.35	0.00
Interest Expense	85	107	63	21	29	0.91	20	-	0.09	-0.09	-
Interest & Investment Income	14	16	1.05	0.01	0.23	1.94	1.69	0.58	-	-0.44	-
Income Tax Expense	29	28	-3.85	-75	0.83	0.00	0.00	-	-	-	-
Basic Earnings per Share	$2.14	$1.43	($0.74)	$2.05	$0.78	($0.68)	($1.19)	($2.47)	($3.88)	($1.48)	($22.72)
Weighted Average Basic Shares Outstanding	32.27M	33.74M	33.83M	34.94M	34.41M	33.45M	32.95M	30.27M	24.26M	13.54M	934.00K
Diluted Earnings per Share	$1.86	$1.29	($0.74)	$1.86	$0.76	($0.68)	($1.19)	($2.47)	($3.88)	($1.48)	($22.72)
Weighted Average Diluted Shares Outstanding	40.42M	41.79M	33.83M	41.05M	35.15M	33.45M	32.95M	30.27M	24.26M	13.54M	934.00K
Weighted Average Basic & Diluted Shares Outstanding	31.49M	31.96M	34.07M	33.38M	34.76M	33.45M	32.95M	30.27M	24.26M	13.54M	934.00K

This table shows Collegium Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	2.42	13	9.34	20	28	32	21	13	-17	-7.20	0.46
Consolidated Net Income / (Loss)	2.42	13	9.34	20	28	32	21	13	-17	-7.20	0.46
Net Income / (Loss) Continuing Operations	2.42	13	9.34	20	28	32	21	13	-17	-7.20	0.46
Total Pre-Tax Income	3.12	17	16	29	37	47	29	18	-18	-7.79	1.43
Total Operating Income	22	38	35	47	49	62	45	36	25	12	20
Total Gross Profit	97	98	97	91	91	95	80	74	77	50	59
Total Revenue	178	182	159	145	145	150	137	136	145	130	127
Operating Revenue	178	182	159	145	145	150	137	136	145	130	127
Total Cost of Revenue	80	84	63	54	53	55	56	62	67	80	68
Operating Cost of Revenue	80	84	63	54	53	55	56	62	67	80	68
Total Operating Expenses	76	60	62	43	42	33	35	38	53	38	38
Selling, General & Admin Expense	76	63	62	43	42	33	35	38	53	38	38
Other Special Charges / (Income)	-0.79	-	-	-	-	-	-	-	-	-	-
Total Other Income / (Expense), net	-19	-21	-19	-18	-13	-15	-16	-18	-42	-20	-19
Interest Expense	21	23	23	23	17	19	21	22	45	21	19
Interest & Investment Income	2.23	1.81	3.28	4.40	4.49	4.30	4.54	4.03	2.75	1.03	0.01
Income Tax Expense	0.71	4.73	6.25	9.49	8.91	15	8.15	4.79	-0.13	-0.59	0.98
Basic Earnings per Share	$0.08	$0.39	$0.29	$0.60	$0.86	$0.95	$0.61	$0.38	($0.51)	($0.21)	$0.01
Weighted Average Basic Shares Outstanding	31.79M	32.27M	32.26M	32.43M	32.33M	33.74M	33.74M	34.62M	34.32M	33.83M	34.06M
Diluted Earnings per Share	$0.07	$0.36	$0.27	$0.52	$0.71	$0.93	$0.53	$0.34	($0.51)	($0.21)	$0.01
Weighted Average Diluted Shares Outstanding	32.84M	40.42M	40.16M	40.38M	41.44M	41.79M	42.06M	42.85M	34.32M	33.83M	34.57M
Weighted Average Basic & Diluted Shares Outstanding	32.14M	31.49M	32.25M	32.21M	32.72M	31.96M	32.61M	34.73M	34.59M	34.07M	33.57M

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	-143	64	-13	12	6.64	23	28	-35	58	94	-5.92
Net Cash From Operating Activities	205	275	124	104	94	28	169	-67	-75	-22	-18
Net Cash From Continuing Operating Activities	205	275	124	104	94	28	169	-67	-75	-22	-18
Net Income / (Loss) Continuing Operations	69	48	-25	72	27	-23	-39	-75	-94	-27	-18
Consolidated Net Income / (Loss)	69	48	-25	72	27	-23	-39	-75	-94	-27	-18
Depreciation Expense	3.86	3.50	2.68	1.74	0.87	0.73	1.07	0.59	0.66	0.17	0.19
Amortization Expense	169	153	145	71	70	15	110	-0.03	-0.03	-0.03	-0.03
Non-Cash Adjustments To Reconcile Net Income	48	47	0.35	65	21	30	140	26	5.79	2.22	0.02
Changes in Operating Assets and Liabilities, net	-85	23	1.66	-105	-24	5.42	-42	-18	13	3.34	-0.22
Net Cash From Investing Activities	-288	-71	-574	-1.94	-374	-6.44	-24	-0.99	-2.98	-0.36	-0.01
Net Cash From Continuing Investing Activities	-288	-71	-574	-1.94	-374	-6.44	-24	-0.99	-2.98	-0.36	-0.01
Purchase of Property, Plant & Equipment	-1.65	-0.46	-1.62	-1.94	-5.55	-6.44	-5.48	-0.99	-0.48	-0.36	-0.01
Acquisitions	-268	0.00	-572	0.00	-368	0.00	-19	-	-2.50	0.00	0.00
Purchase of Investments	-111	-92	0.00	0.00	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	93	22	0.00	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	-61	-140	437	-89	286	2.04	-117	33	136	116	12
Net Cash From Continuing Financing Activities	-61	-140	437	-89	286	2.04	-117	33	136	116	12
Repayment of Debt	-272	-301	-75	-50	-49	0.00	0.00	-2.67	-2.67	-1.36	-0.03
Repurchase of Common Equity	-60	-75	-14	-48	0.00	0.00	-0.03	-	-	-	-
Issuance of Debt	0.00	235	518	0.00	330	0.00	10	-	-	0.00	12
Issuance of Common Equity	0.83	0.46	0.34	0.76	0.76	0.82	1.12	35	138	72	0.00
Other Financing Activities, net	271	0.28	7.77	7.80	4.32	1.22	-128	0.67	0.44	0.52	0.01
Cash Interest Paid	62	73	53	18	19	0.71	-	0.14	0.28	0.35	0.18
Cash Income Taxes Paid	52	24	10	3.01	0.48	0.00	0.00	-	-	-	-

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	20	32	-109	-56	-10	-20	-25	13	96	40	11
Net Cash From Operating Activities	55	85	-9.00	67	62	73	74	100	28	66	43
Net Cash From Continuing Operating Activities	55	85	-9.47	67	62	73	74	100	28	66	43
Net Income / (Loss) Continuing Operations	2.42	13	9.34	20	28	32	21	13	-17	-7.20	0.46
Consolidated Net Income / (Loss)	2.42	13	9.34	20	28	32	21	13	-17	-7.20	0.46
Depreciation Expense	1.09	1.04	0.95	0.95	0.92	0.95	0.84	0.90	0.82	0.83	0.49
Amortization Expense	57	57	41	35	36	36	38	40	40	45	40
Non-Cash Adjustments To Reconcile Net Income	13	4.23	10	36	-2.00	-11	39	19	-0.16	-5.16	-0.21
Changes in Operating Assets and Liabilities, net	-17	11	-71	-24	-0.58	15	-24	27	4.68	33	2.02
Net Cash From Investing Activities	-9.68	-12	-249	-8.91	-18	-25	-3.82	-42	-0.18	-0.94	-0.11
Net Cash From Continuing Investing Activities	-9.68	-12	-249	-8.91	-18	-25	-3.82	-42	-0.18	-0.94	-0.11
Purchase of Property, Plant & Equipment	-0.80	-0.57	-0.24	-0.27	-0.57	-0.16	-0.07	-0.06	-0.18	-0.94	-0.11
Purchase of Investments	-26	-27	-11	-34	-39	-41	-9.76	-42	0.00	-	-
Sale and/or Maturity of Investments	17	16	29	26	22	16	6.00	-	0.00	-	-
Net Cash From Financing Activities	-25	-41	149	-114	-54	-68	-95	-45	68	-26	-31
Net Cash From Continuing Financing Activities	-25	-41	149	-114	-54	-68	-95	-45	68	-26	-31
Repayment of Debt	-16	17	-165	-79	-46	-46	-46	-46	-164	-25	-25
Issuance of Common Equity	0.51	-	0.47	-	0.36	-	0.29	-	0.17	-	0.13
Other Financing Activities, net	-9.60	280	0.01	-0.16	-8.67	3.01	0.13	1.03	-3.89	6.82	0.04
Cash Interest Paid	22	15	18	12	17	16	20	18	19	17	18
Cash Income Taxes Paid	2.46	0.62	16	36	0.17	6.91	7.28	9.27	0.74	0.36	3.26

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	1,664	1,143	1,174	692	644	306	291	136	162	98	5.09
Total Current Assets	482	538	420	316	278	256	238	133	159	97	4.50
Cash & Equivalents	71	239	174	186	174	170	147	119	153	96	1.63
Restricted Cash	25	0.00	-	-	-	-	-	-	-	-	-
Short-Term Investments	92	72	0.00	-	-	-	-	-	-	-	-
Accounts Receivable	229	180	183	106	83	73	78	9.97	2.13	0.00	-
Inventories, net	36	32	47	17	16	9.64	7.82	1.81	1.32	0.00	-
Prepaid Expenses	30	15	17	5.88	4.84	3.11	5.12	3.01	1.91	1.19	0.53
Plant, Property, & Equipment, net	14	16	20	19	19	12	9.27	1.83	1.04	0.74	0.51
Total Noncurrent Assets	1,167	590	735	357	347	39	44	0.26	2.40	0.10	0.08
Goodwill	162	134	134	0.00	336	30	44	-	2.10	0.00	-
Intangible Assets	891	422	567	269	-	-	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	98	26	24	78	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	15	7.90	6.96	7.73	8.51	9.23	0.20	0.16	0.20	0.00	-
Total Liabilities & Shareholders' Equity	1,664	1,143	1,174	692	644	306	291	136	162	98	5.09
Total Liabilities	1,435	948	979	489	458	219	200	31	27	13	17
Total Current Liabilities	510	458	434	280	239	202	189	31	26	8.43	10
Short-Term Debt	94	183	163	48	47	3.83	1.64	1.48	-	2.67	6.19
Accounts Payable	3.93	8.69	3.49	4.19	10	6.25	12	5.68	9.11	3.54	2.21
Accrued Expenses	411	265	267	226	181	191	175	24	8.88	2.23	1.96
Other Current Liabilities	1.27	0.99	1.11	0.81	0.73	0.66	-	-	-	-	0.06
Total Noncurrent Liabilities	925	490	546	210	218	17	11	0.00	1.51	4.21	6.91
Long-Term Debt	788	484	538	202	210	7.67	9.86	-	1.48	4.15	6.81
Noncurrent Deferred Revenue	10	0.00	-	-	-	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	127	6.12	7.11	7.95	8.77	9.44	0.68	-	0.03	0.07	0.10
Commitments & Contingencies	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	229	195	195	203	186	87	92	104	135	85	-89
Total Preferred & Common Equity	229	195	195	203	186	87	92	104	135	85	-89
Preferred Stock	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Common Equity	229	195	195	203	186	87	92	104	135	85	-89
Common Stock	590	566	538	502	519	447	429	402	358	214	12
Retained Earnings	-164	-233	-281	-256	-333	-360	-337	-298	-223	-129	-102
Treasury Stock	-198	-137	-62	-43	-	-	-	-	-	-0.00	-0.00
Accumulated Other Comprehensive Income / (Loss)	0.06	0.01	0.00	-	-	-	-	-	-	-	-

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,631	1,635	1,053	1,114	1,178	1,214	1,214	1,201
Total Current Assets	528	444	510	539	537	537	498	405
Cash & Equivalents	96	39	173	229	259	284	269	134
Restricted Cash	20	25	-	-	-	-	-	-
Short-Term Investments	102	81	99	89	46	42	-	-
Accounts Receivable	229	228	184	175	182	167	179	195
Inventories, net	37	38	28	31	34	26	33	65
Prepaid Expenses	44	32	27	15	17	18	17	11
Plant, Property, & Equipment, net	14	15	15	15	17	18	19	20
Total Noncurrent Assets	1,090	1,177	528	560	624	659	697	776
Goodwill	151	146	134	134	134	134	134	130
Intangible Assets	836	947	353	387	456	493	530	610
Noncurrent Deferred & Refundable Income Taxes	92	73	34	31	26	25	24	26
Other Noncurrent Operating Assets	12	11	6.45	6.77	6.98	6.53	6.75	7.12
Total Liabilities & Shareholders' Equity	1,631	1,635	1,053	1,114	1,178	1,214	1,214	1,201
Total Liabilities	1,397	1,401	837	892	999	1,013	1,035	1,004
Total Current Liabilities	487	459	462	446	465	435	413	414
Short-Term Debt	89	94	183	183	183	183	183	142
Accounts Payable	18	3.14	2.41	6.02	3.65	2.42	2.99	7.64
Accrued Expenses	378	361	275	256	277	248	225	264
Other Current Liabilities	1.30	1.27	1.04	1.01	0.96	0.97	1.04	1.18
Total Noncurrent Liabilities	910	941	375	446	534	578	622	589
Long-Term Debt	773	803	369	440	528	571	615	582
Noncurrent Deferred Revenue	10	10	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	127	129	5.59	5.86	6.38	6.63	6.87	7.35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	234	234	217	222	179	201	180	197
Total Preferred & Common Equity	234	234	217	222	179	201	180	197
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	234	234	217	222	179	201	180	197
Common Stock	593	583	568	565	546	549	540	526
Retained Earnings	-162	-177	-186	-205	-265	-286	-299	-274
Treasury Stock	-198	-172	-165	-137	-102	-62	-62	-54
Accumulated Other Comprehensive Income / (Loss)	0.24	0.39	-0.18	-0.12	-0.05	-0.04	-	-

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.41%	22.17%	67.56%	-10.69%	4.49%	5.81%	884.73%	1,564.29%	0.00%	0.00%	0.00%
EBITDA Growth	6.00%	79.25%	100.71%	-29.04%	1,633.62%	-109.16%	220.48%	19.87%	-249.13%	-16,831.25%	101.01%
EBIT Growth	1.76%	401.10%	89.01%	-68.65%	336.79%	-14.81%	72.58%	19.81%	-249.66%	0.00%	100.00%
NOPAT Growth	12.34%	355.18%	89.01%	-77.38%	428.09%	-14.81%	72.58%	19.81%	-249.66%	0.00%	100.00%
Net Income Growth	43.68%	292.60%	-134.96%	167.33%	217.74%	41.93%	47.74%	20.51%	-245.54%	0.00%	100.00%
EPS Growth	44.19%	274.32%	-139.78%	144.74%	211.76%	42.86%	51.82%	36.34%	-162.16%	93.49%	-459.61%
Operating Cash Flow Growth	-25.39%	121.16%	19.96%	10.24%	238.13%	-83.60%	352.75%	10.71%	-248.00%	-20.17%	-8.57%
Free Cash Flow Firm Growth	-191.79%	163.31%	-3,009.78%	105.25%	-2,692.71%	-31.06%	128.02%	-6.97%	-232.82%	-1,774.46%	0.00%
Invested Capital Growth	67.11%	-23.28%	172.62%	-0.94%	474.83%	-63.24%	-229.04%	21.85%	-333.23%	-312.34%	0.00%
Revenue Q/Q Growth	5.37%	3.68%	28.27%	-15.01%	0.67%	0.26%	28.76%	49.99%	319.36%	0.00%	0.00%
EBITDA Q/Q Growth	-0.83%	14.63%	68.46%	-36.07%	35.35%	-148.44%	97.42%	39.88%	-89.35%	-346.59%	0.00%
EBIT Q/Q Growth	-12.19%	42.67%	365.28%	-73.59%	44.69%	-128.92%	58.02%	39.88%	-89.23%	-351.30%	0.00%
NOPAT Q/Q Growth	-10.94%	113.62%	365.28%	-92.36%	40.34%	-128.92%	58.02%	39.88%	-89.23%	-275.91%	0.00%
Net Income Q/Q Growth	-21.90%	434.11%	41.63%	-30.91%	52.06%	-98.71%	40.37%	11.95%	-16.53%	-2,060.79%	0.00%
EPS Q/Q Growth	-23.46%	760.00%	32.11%	-29.01%	55.10%	-106.06%	39.90%	17.11%	-108.60%	78.83%	0.00%
Operating Cash Flow Q/Q Growth	5.84%	2.62%	32.01%	15.15%	7.95%	-48.94%	48.84%	12.97%	-23.64%	-6.79%	0.00%
Free Cash Flow Firm Q/Q Growth	6.01%	9.69%	19.78%	-91.72%	2.74%	-90.04%	115.43%	37.59%	-93.29%	0.00%	0.00%
Invested Capital Q/Q Growth	-6.39%	-5.52%	-8.23%	3.92%	-1.95%	-22.40%	-174.03%	-42.42%	-41.28%	13.44%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.76%	57.55%	45.15%	54.40%	58.01%	34.73%	40.92%	90.89%	87.55%	0.00%	0.00%
EBITDA Margin	54.33%	57.10%	38.92%	32.49%	40.89%	-2.79%	32.18%	-262.98%	-5,462.36%	0.00%	0.00%
Operating Margin	26.91%	29.46%	7.18%	6.37%	18.14%	-8.00%	-7.38%	-264.95%	-5,498.66%	0.00%	0.00%
EBIT Margin	26.91%	29.46%	7.18%	6.37%	18.14%	-8.00%	-7.38%	-264.95%	-5,498.66%	0.00%	0.00%
Profit (Net Income) Margin	10.96%	8.50%	-5.39%	25.83%	8.63%	-7.66%	-13.95%	-262.91%	-5,504.15%	0.00%	0.00%
Tax Burden Percent	70.20%	63.59%	86.67%	-2,119.65%	96.99%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Interest Burden Percent	58.02%	45.36%	-86.58%	-19.14%	49.05%	95.68%	189.16%	99.23%	100.10%	101.29%	0.00%
Effective Tax Rate	29.80%	36.41%	0.00%	0.00%	3.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	16.18%	16.70%	4.74%	4.65%	55.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	6.64%	3.53%	-11.76%	88.33%	127.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	16.44%	7.98%	-17.31%	32.12%	-36.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	32.62%	24.68%	-12.57%	36.77%	19.57%	-25.39%	-39.99%	-62.65%	-85.62%	-74.84%	0.00%
Cash Return on Invested Capital (CROIC)	-34.07%	43.04%	-87.91%	5.60%	-106.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	12.11%	14.41%	3.57%	2.64%	11.84%	-7.95%	-9.69%	-50.71%	-72.44%	0.00%	0.00%
Return on Assets (ROA)	4.93%	4.16%	-2.68%	10.71%	5.63%	-7.61%	-18.34%	-50.32%	-72.52%	0.00%	0.00%
Return on Common Equity (ROCE)	32.62%	24.68%	-12.57%	36.77%	19.57%	-25.39%	-39.99%	-62.65%	-85.62%	4.39%	0.00%
Return on Equity Simple (ROE_SIMPLE)	30.23%	24.64%	-12.83%	35.24%	14.38%	-25.99%	-42.72%	-71.93%	-69.81%	-32.04%	0.00%
Net Operating Profit after Tax (NOPAT)	119	106	23	12	55	-17	-14	-53	-66	-19	0.00
NOPAT Margin	18.89%	18.73%	5.03%	4.46%	17.59%	-5.60%	-5.16%	-185.46%	-3,849.06%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	9.53%	13.16%	16.50%	-83.68%	-71.17%	-4.15%	-19.53%	-16.39%	-23.52%	-21.68%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	10.74%	12.31%	2.60%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	40.24%	42.45%	54.85%	45.60%	41.99%	65.27%	59.08%	9.11%	12.45%	0.00%	0.00%
SG&A Expenses to Revenue	33.31%	28.09%	37.11%	42.97%	36.72%	39.25%	45.20%	325.73%	4,712.57%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.86%	3.41%	3.15%	3.49%	3.09%	30.10%	873.64%	0.00%	0.00%
Operating Expenses to Revenue	32.85%	28.09%	37.97%	48.03%	39.87%	42.73%	48.29%	355.84%	5,586.21%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	170	167	33	18	56	-24	-21	-75	-94	-27	0.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	343	324	181	90	127	-8.27	90	-75	-93	-27	0.16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.04	5.14	4.00	3.18	3.72	7.89	6.23	5.78	3.30	6.69	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	11.91	12.06	5.78	3.35	6.69	0.00
Price to Revenue (P/Rev)	1.46	1.77	1.68	2.33	2.23	2.33	2.04	21.11	260.35	0.00	0.00
Price to Earnings (P/E)	13.35	20.84	0.00	9.03	25.89	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.49%	4.80%	0.00%	11.08%	3.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.75	2.46	1.82	2.69	2.91	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.56	2.40	2.82	2.56	2.50	1.79	1.55	16.99	171.67	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	4.72	4.20	7.23	7.89	6.12	0.00	4.83	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	9.52	8.15	39.20	40.24	13.79	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	13.56	12.81	56.00	57.48	14.22	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.89	4.95	10.51	6.85	8.26	19.13	2.57	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	4.97	0.00	47.74	0.00	48.69	27.52	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.85	3.41	3.60	1.23	1.38	0.13	0.13	0.01	0.01	0.08	-1.06
Long-Term Debt to Equity	3.44	2.48	2.76	0.99	1.13	0.09	0.11	0.00	0.01	0.05	-0.56
Financial Leverage	2.48	2.26	1.47	0.36	-0.29	-1.64	-1.29	-1.13	-1.09	-1.07	-0.92
Leverage Ratio	6.62	5.94	4.69	3.43	3.47	3.34	2.18	1.25	1.18	1.41	-0.42
Compound Leverage Factor	3.84	2.69	-4.06	-0.66	1.70	3.19	4.13	1.24	1.18	1.43	0.00
Debt to Total Capital	79.39%	77.34%	78.25%	55.19%	58.02%	11.62%	11.16%	1.40%	1.08%	7.41%	1,698.04%
Short-Term Debt to Total Capital	8.42%	21.25%	18.14%	10.68%	10.72%	3.87%	1.59%	1.40%	0.00%	2.90%	808.62%
Long-Term Debt to Total Capital	70.96%	56.09%	60.11%	44.52%	47.30%	7.75%	9.56%	0.00%	1.08%	4.51%	889.43%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10,066.19%
Common Equity to Total Capital	20.61%	22.66%	21.75%	44.81%	41.98%	88.38%	88.84%	98.60%	98.92%	92.59%	-11,664.23%
Debt to EBITDA	2.57	2.06	3.88	2.78	2.03	-1.39	0.13	-0.02	-0.02	-0.25	81.29
Net Debt to EBITDA	2.02	1.10	2.92	0.71	0.65	19.18	-1.50	1.57	1.62	3.32	71.08
Long-Term Debt to EBITDA	2.30	1.50	2.98	2.24	1.65	-0.93	0.11	0.00	-0.02	-0.15	42.58
Debt to NOPAT	7.39	6.28	30.05	20.26	4.71	-0.69	-0.79	-0.03	-0.02	-0.36	0.00
Net Debt to NOPAT	5.82	3.36	22.61	5.15	1.52	9.54	9.33	2.22	2.30	4.72	0.00
Long-Term Debt to NOPAT	6.61	4.56	23.09	16.34	3.84	-0.46	-0.68	0.00	-0.02	-0.22	0.00
Altman Z-Score	0.95	1.41	0.62	0.82	1.02	1.17	1.02	7.65	7.01	25.32	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	105.87%	-629.91%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.95	1.17	0.97	1.13	1.16	1.27	1.26	4.24	6.20	11.49	0.43
Quick Ratio	0.77	1.07	0.82	1.05	1.08	1.20	1.19	4.09	6.07	11.35	0.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-251	274	-432	15	-283	11	16	-57	-53	-16	0.95
Operating Cash Flow to CapEx	12,407.99%	59,598.48%	7,659.06%	5,327.01%	1,693.87%	431.55%	3,092.75%	-6,769.49%	-15,734.38%	-5,957.73%	-224,337.50%
Free Cash Flow to Firm to Interest Expense	-2.94	2.56	-6.84	0.71	-9.80	12.01	0.79	0.00	-562.04	0.00	0.00
Operating Cash Flow to Interest Expense	2.40	2.57	1.97	4.93	3.25	30.56	8.41	0.00	-798.44	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	2.38	2.57	1.94	4.84	3.06	23.48	8.14	0.00	-803.51	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.49	0.50	0.41	0.65	0.99	1.31	0.19	0.01	0.00	0.00
Accounts Receivable Turnover	3.09	3.13	3.21	2.93	3.97	3.93	6.38	4.71	0.00	0.00	0.00
Inventory Turnover	7.49	6.10	7.96	7.65	10.31	22.18	34.41	1.66	0.00	0.00	0.00
Fixed Asset Turnover	41.66	31.93	23.78	14.39	20.10	28.09	50.52	19.89	1.93	0.00	0.00
Accounts Payable Turnover	40.25	39.49	66.24	17.78	16.01	21.05	18.58	0.35	0.03	0.00	0.00
Days Sales Outstanding (DSO)	117.94	116.77	113.67	124.69	91.99	92.82	57.22	77.53	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	48.76	59.80	45.83	47.71	35.41	16.45	10.61	220.05	0.00	0.00	0.00
Days Payable Outstanding (DPO)	9.07	9.24	5.51	20.53	22.80	17.34	19.64	1,040.14	10,832.62	0.00	0.00
Cash Conversion Cycle (CCC)	157.63	167.33	153.99	151.87	104.60	91.93	48.18	-742.55	-10,832.62	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	923	552	720	264	266	-71	-44	-13	-17	-3.91	-0.95
Invested Capital Turnover	0.86	0.89	0.94	1.04	3.17	-5.18	-9.88	-1.89	-0.16	0.00	0.00
Increase / (Decrease) in Invested Capital	370	-168	456	-2.52	338	-28	-30	3.70	-13	-2.96	-0.95
Enterprise Value (EV)	1,618	1,360	1,306	709	776	531	436	484	294	480	0.00
Market Capitalization	924	1,004	779	646	693	690	571	601	445	569	0.00
Book Value per Share	$7.10	$5.99	$5.80	$5.87	$5.38	$2.61	$2.75	$3.20	$4.72	$4.11	($95.66)
Tangible Book Value per Share	($25.58)	($11.04)	($15.08)	($1.90)	($4.33)	$1.73	$1.42	$3.20	$4.64	$4.11	($95.66)
Total Capital	1,110	863	896	453	443	99	103	106	136	92	0.77
Total Debt	881	667	701	250	257	12	12	1.48	1.48	6.81	13
Total Long-Term Debt	788	484	538	202	210	7.67	9.86	0.00	1.48	4.15	6.81
Net Debt	694	357	527	64	83	-159	-135	-117	-152	-89	11
Capital Expenditures (CapEx)	1.65	0.46	1.62	1.94	5.55	6.44	5.48	0.99	0.48	0.36	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-121	-48	-25	-102	-88	-112	-97	-15	-20	-4.58	-1.36
Debt-free Net Working Capital (DFNWC)	66	263	149	84	86	58	50	103	133	91	0.27
Net Working Capital (NWC)	-27	80	-14	36	38	54	48	102	133	88	-5.92
Net Nonoperating Expense (NNE)	50	58	48	-59	28	6.10	25	22	28	8.42	0.00
Net Nonoperating Obligations (NNO)	694	357	525	61	80	-159	-135	-117	-152	-89	11
Total Depreciation and Amortization (D&A)	173	157	147	72	71	15	111	0.56	0.62	0.14	0.16
Debt-free, Cash-free Net Working Capital to Revenue	-19.24%	-8.39%	-5.37%	-36.88%	-28.45%	-37.83%	-34.45%	-53.46%	-1,183.28%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	10.50%	46.41%	32.07%	30.46%	27.72%	19.48%	17.84%	363.38%	7,772.00%	0.00%	0.00%
Net Working Capital to Revenue	-4.32%	14.06%	-2.96%	12.99%	12.40%	18.19%	17.26%	358.18%	7,772.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.14	$1.43	$0.00	$0.00	$0.00	($0.68)	($1.19)	($2.47)	($3.88)	($1.48)	($22.72)
Adjusted Weighted Average Basic Shares Outstanding	32.27M	33.74M	0.00	0.00	0.00	34.05M	33.31M	32.99M	29.45M	23.51M	934.00K
Adjusted Diluted Earnings per Share	$1.86	$1.29	$0.00	$0.00	$0.00	($0.68)	($1.19)	($2.47)	($94,176,000.00)	($1.48)	($22.72)
Adjusted Weighted Average Diluted Shares Outstanding	40.42M	41.79M	0.00	0.00	0.00	34.05M	33.31M	32.99M	29.45M	23.51M	934.00K
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.68)	($1.19)	($2.47)	($94,176,000.00)	($1.48)	($22.72)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.49M	31.96M	0.00	0.00	0.00	33.45M	32.95M	30.27M	24.26M	13.54M	934.00K
Normalized Net Operating Profit after Tax (NOPAT)	117	106	23	16	55	-17	-14	-53	-66	-19	0.00
Normalized NOPAT Margin	18.56%	18.73%	5.03%	5.61%	17.59%	-5.60%	-5.16%	-185.46%	-3,849.06%	0.00%	0.00%
Pre Tax Income Margin	15.61%	13.36%	-6.22%	-1.22%	8.90%	-7.66%	-13.95%	-262.91%	-5,504.15%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.99	1.56	0.53	0.84	1.95	-26.13	-1.03	0.00	-1,000.87	0.00	0.00
NOPAT to Interest Expense	1.40	0.99	0.37	0.59	1.89	-18.29	-0.72	0.00	-700.61	0.00	0.00
EBIT Less CapEx to Interest Expense	1.97	1.56	0.50	0.75	1.75	-33.21	-1.30	0.00	-1,005.95	0.00	0.00
NOPAT Less CapEx to Interest Expense	1.38	0.99	0.34	0.49	1.70	-25.37	-0.99	0.00	-705.69	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	86.75%	155.75%	-56.25%	66.92%	0.00%	0.00%	-0.08%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.66%	21.51%	16.53%	7.18%	0.11%	15.53%	7.63%	9.71%	72.85%	373.72%	61.10%
EBITDA Growth	-8.09%	-2.92%	-7.69%	10.07%	32.33%	72.15%	37.30%	47.05%	518.80%	455.02%	89.21%
EBIT Growth	-56.16%	-38.22%	-22.60%	33.22%	100.89%	424.69%	119.93%	220.73%	345.90%	134.46%	44.65%
NOPAT Growth	-55.15%	-34.41%	-35.31%	22.82%	117.17%	412.54%	394.04%	234.87%	345.90%	134.46%	-48.15%
Net Income Growth	-91.28%	-60.75%	-54.76%	50.73%	259.03%	543.67%	4,415.10%	350.57%	-33.34%	71.24%	-94.32%
EPS Growth	-90.14%	-61.29%	-49.06%	52.94%	239.22%	542.86%	5,200.00%	326.67%	-30.77%	62.50%	-95.45%
Operating Cash Flow Growth	-10.56%	15.42%	-112.16%	-32.41%	123.83%	10.57%	73.06%	146.53%	209.31%	83.23%	147.88%
Free Cash Flow Firm Growth	-254.69%	-263.48%	-263.89%	-23.74%	30.40%	146.87%	144.32%	144.01%	128.11%	-1,993.69%	-1,823.90%
Invested Capital Growth	67.06%	67.11%	68.66%	-21.03%	-25.47%	-23.28%	-25.48%	-23.14%	-17.46%	172.62%	208.72%
Revenue Q/Q Growth	-2.30%	14.22%	9.65%	0.24%	-3.22%	9.54%	0.86%	-6.37%	11.69%	2.05%	2.80%
EBITDA Q/Q Growth	-17.12%	23.80%	-7.80%	-2.84%	-12.45%	17.71%	9.94%	16.81%	13.89%	-6.12%	17.74%
EBIT Q/Q Growth	-43.10%	9.39%	-26.61%	-4.05%	-19.80%	37.04%	26.32%	44.69%	109.47%	-42.56%	84.22%
NOPAT Q/Q Growth	-39.31%	32.53%	-34.74%	-14.56%	-11.25%	30.72%	23.91%	51.07%	109.47%	26.00%	-16.01%
Net Income Q/Q Growth	-80.72%	34.29%	-52.39%	-29.25%	-13.23%	54.79%	58.64%	174.64%	-142.06%	-1,675.27%	108.80%
EPS Q/Q Growth	-80.56%	33.33%	-48.08%	-26.76%	-23.66%	75.47%	55.88%	166.67%	-142.86%	-2,200.00%	106.67%
Operating Cash Flow Q/Q Growth	-34.55%	1,040.59%	-113.35%	8.82%	-15.55%	-0.92%	-25.78%	260.38%	-58.28%	55.08%	5.73%
Free Cash Flow Firm Q/Q Growth	1.96%	9.86%	-331.48%	-24.39%	3.11%	-9.64%	7.71%	29.31%	137.24%	14.55%	-6.95%
Invested Capital Q/Q Growth	-4.71%	-6.39%	98.39%	-5.60%	-4.50%	-5.52%	-7.11%	-10.90%	-1.88%	-8.23%	-4.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.75%	54.02%	60.76%	62.51%	63.11%	63.19%	58.75%	54.47%	53.47%	38.41%	46.33%
EBITDA Margin	44.61%	52.58%	48.51%	57.70%	59.53%	65.81%	61.24%	56.18%	45.04%	44.16%	48.01%
Operating Margin	12.20%	20.95%	21.87%	32.68%	34.14%	41.20%	32.93%	26.29%	17.01%	9.07%	16.11%
EBIT Margin	12.20%	20.95%	21.87%	32.68%	34.14%	41.20%	32.93%	26.29%	17.01%	9.07%	16.11%
Profit (Net Income) Margin	1.36%	6.89%	5.86%	13.50%	19.12%	21.33%	15.09%	9.60%	-12.04%	-5.55%	0.36%
Tax Burden Percent	77.42%	72.59%	59.92%	67.38%	75.67%	68.38%	71.69%	73.09%	99.25%	92.40%	31.91%
Interest Burden Percent	14.40%	45.31%	44.72%	61.29%	74.02%	75.72%	63.94%	49.95%	-71.29%	-66.27%	7.00%
Effective Tax Rate	22.58%	27.41%	40.08%	32.62%	24.33%	31.62%	28.31%	26.91%	0.00%	0.00%	68.09%
Return on Invested Capital (ROIC)	8.93%	13.02%	10.00%	22.56%	23.77%	25.11%	18.86%	14.25%	8.01%	5.99%	3.58%
ROIC Less NNEP Spread (ROIC-NNEP)	5.90%	10.14%	8.01%	19.06%	21.43%	22.79%	16.51%	11.77%	2.16%	0.72%	1.46%
Return on Net Nonoperating Assets (RNNOA)	12.26%	25.11%	22.42%	32.35%	44.27%	51.46%	43.57%	30.99%	6.81%	1.06%	1.79%
Return on Equity (ROE)	21.19%	38.13%	32.43%	54.91%	68.04%	76.57%	62.43%	45.24%	14.82%	7.05%	5.38%
Cash Return on Invested Capital (CROIC)	-36.58%	-34.07%	-34.05%	49.10%	51.55%	43.04%	36.46%	35.12%	25.23%	-87.91%	-103.83%
Operating Return on Assets (OROA)	5.90%	9.42%	9.32%	16.62%	16.62%	20.15%	15.13%	11.48%	7.26%	4.51%	6.00%
Return on Assets (ROA)	0.66%	3.10%	2.50%	6.86%	9.31%	10.43%	6.94%	4.19%	-5.14%	-2.76%	0.13%
Return on Common Equity (ROCE)	21.19%	38.13%	32.43%	54.91%	68.04%	76.57%	62.43%	45.24%	14.82%	7.05%	5.38%
Return on Equity Simple (ROE_SIMPLE)	18.72%	0.00%	37.82%	46.12%	41.99%	0.00%	5.04%	-5.56%	-16.33%	0.00%	-21.72%
Net Operating Profit after Tax (NOPAT)	17	28	21	32	37	42	32	26	17	8.23	6.53
NOPAT Margin	9.45%	15.21%	13.10%	22.02%	25.83%	28.17%	23.60%	19.21%	11.91%	6.35%	5.14%
Net Nonoperating Expense Percent (NNEP)	3.03%	2.88%	2.00%	3.50%	2.34%	2.32%	2.35%	2.49%	5.85%	5.27%	2.12%
Return On Investment Capital (ROIC_SIMPLE)	1.53%	2.49%	-	-	-	4.89%	-	-	-	0.92%	-
Cost of Revenue to Revenue	45.25%	45.98%	39.24%	37.49%	36.89%	36.81%	41.25%	45.53%	46.53%	61.59%	53.67%
SG&A Expenses to Revenue	42.99%	34.68%	38.89%	29.83%	28.97%	22.00%	25.82%	28.18%	36.46%	29.34%	30.21%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	42.55%	33.07%	38.89%	29.83%	28.97%	22.00%	25.82%	28.18%	36.46%	29.34%	30.21%
Earnings before Interest and Taxes (EBIT)	22	38	35	47	49	62	45	36	25	12	20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	79	96	77	84	86	99	84	76	65	57	61
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.01	4.04	5.31	4.86	5.70	5.14	4.34	3.70	4.55	4.00	2.77
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.41	1.46	2.08	1.83	2.23	1.77	1.42	1.38	1.56	1.68	1.51
Price to Earnings (P/E)	21.41	13.35	14.05	10.55	13.57	20.84	86.10	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.67%	7.49%	7.12%	9.48%	7.37%	4.80%	1.16%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.80	1.75	2.03	2.69	2.99	2.46	2.02	1.86	1.91	1.82	1.45
Enterprise Value to Revenue (EV/Rev)	2.39	2.56	3.33	2.31	2.77	2.40	2.16	2.18	2.56	2.82	3.14
Enterprise Value to EBITDA (EV/EBITDA)	4.71	4.72	5.77	3.79	4.56	4.20	4.19	4.52	5.72	7.23	10.60
Enterprise Value to EBIT (EV/EBIT)	11.15	9.52	10.32	6.55	8.19	8.15	10.11	12.68	19.81	39.20	0.00
Enterprise Value to NOPAT (EV/NOPAT)	16.53	13.56	14.91	9.26	11.41	12.81	23.80	18.11	28.30	56.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.98	7.89	10.31	4.82	5.08	4.95	4.42	4.96	7.60	10.51	12.07
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	4.83	4.95	4.97	4.74	4.61	6.83	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.68	3.85	3.83	2.55	2.80	3.41	3.98	3.76	4.44	3.60	3.67
Long-Term Debt to Equity	3.30	3.44	3.43	1.71	1.98	2.48	2.95	2.85	3.42	2.76	2.95
Financial Leverage	2.08	2.48	2.80	1.70	2.07	2.26	2.64	2.63	3.15	1.47	1.23
Leverage Ratio	6.01	6.62	6.81	5.43	5.79	5.94	6.32	6.17	6.55	4.69	4.17
Compound Leverage Factor	0.87	3.00	3.04	3.33	4.29	4.50	4.04	3.08	-4.67	-3.11	0.29
Debt to Total Capital	78.62%	79.39%	79.28%	71.85%	73.72%	77.34%	79.90%	78.99%	81.62%	78.25%	78.58%
Short-Term Debt to Total Capital	8.13%	8.42%	8.27%	23.83%	21.69%	21.25%	20.60%	19.19%	18.74%	18.14%	15.39%
Long-Term Debt to Total Capital	70.50%	70.96%	71.00%	48.02%	52.03%	56.09%	59.30%	59.80%	62.88%	60.11%	63.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	21.38%	20.61%	20.72%	28.15%	26.28%	22.66%	20.10%	21.01%	18.38%	21.75%	21.42%
Debt to EBITDA	2.57	2.57	2.59	1.57	1.81	2.06	2.52	2.91	3.39	3.88	6.75
Net Debt to EBITDA	1.92	2.02	2.17	0.80	0.89	1.10	1.44	1.65	2.25	2.92	5.50
Long-Term Debt to EBITDA	2.30	2.30	2.32	1.05	1.28	1.50	1.87	2.20	2.61	2.98	5.43
Debt to NOPAT	8.99	7.39	6.69	3.84	4.52	6.28	14.31	11.66	16.78	30.05	-82.30
Net Debt to NOPAT	6.72	5.82	5.61	1.95	2.21	3.36	8.18	6.63	11.12	22.61	-67.04
Long-Term Debt to NOPAT	8.06	6.61	5.99	2.56	3.19	4.56	10.62	8.83	12.93	23.09	-66.19
Altman Z-Score	0.75	0.68	0.81	1.26	1.35	1.11	0.82	0.75	0.71	0.56	0.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.08	0.95	0.97	1.11	1.21	1.17	1.16	1.24	1.21	0.97	0.98
Quick Ratio	0.88	0.77	0.76	0.99	1.10	1.07	1.05	1.13	1.09	0.82	0.80
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-336	-343	-380	164	217	210	232	215	167	-447	-524
Operating Cash Flow to CapEx	6,942.11%	14,849.82%	-3,688.11%	24,962.22%	10,904.40%	44,718.29%	113,873.85%	178,075.00%	15,722.16%	7,055.85%	37,848.67%
Free Cash Flow to Firm to Interest Expense	-16.17	-15.13	-16.87	7.22	12.53	10.88	11.17	9.85	3.71	-21.74	-27.49
Operating Cash Flow to Interest Expense	2.66	3.74	-0.40	2.96	3.57	3.80	3.56	4.56	0.62	3.22	2.25
Operating Cash Flow Less CapEx to Interest Expense	2.63	3.71	-0.41	2.95	3.54	3.80	3.56	4.56	0.61	3.18	2.24
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.45	0.43	0.51	0.49	0.49	0.46	0.44	0.43	0.50	0.37
Accounts Receivable Turnover	3.29	3.09	2.92	3.28	3.20	3.13	2.90	2.94	3.04	3.21	2.10
Inventory Turnover	8.21	7.49	6.25	8.14	7.07	6.10	5.37	5.34	5.07	7.96	4.96
Fixed Asset Turnover	45.33	41.66	38.34	34.93	33.02	31.93	30.04	28.26	26.86	23.78	18.37
Accounts Payable Turnover	23.55	40.25	66.39	90.83	50.31	39.49	47.00	61.26	83.75	66.24	26.46
Days Sales Outstanding (DSO)	110.83	117.94	124.96	111.19	113.90	116.77	125.95	124.05	120.10	113.67	173.78
Days Inventory Outstanding (DIO)	44.47	48.76	58.38	44.81	51.66	59.80	67.95	68.36	71.99	45.83	73.62
Days Payable Outstanding (DPO)	15.50	9.07	5.50	4.02	7.25	9.24	7.77	5.96	4.36	5.51	13.79
Cash Conversion Cycle (CCC)	139.80	157.63	177.84	151.99	158.30	167.33	186.13	186.46	187.74	153.99	233.61
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	879	923	985	497	526	552	584	629	706	720	784
Invested Capital Turnover	0.95	0.86	0.76	1.02	0.92	0.89	0.80	0.74	0.67	0.94	0.70
Increase / (Decrease) in Invested Capital	353	370	401	-132	-180	-168	-200	-189	-149	456	530
Enterprise Value (EV)	1,584	1,618	1,996	1,335	1,571	1,360	1,183	1,173	1,346	1,306	1,136
Market Capitalization	940	924	1,245	1,053	1,266	1,004	776	743	817	779	547
Book Value per Share	$7.45	$7.10	$7.27	$6.62	$6.87	$5.99	$5.15	$5.80	$5.28	$5.80	$5.78
Tangible Book Value per Share	($23.89)	($25.58)	($26.65)	($8.25)	($9.25)	($11.04)	($11.84)	($12.30)	($14.21)	($15.08)	($15.90)
Total Capital	1,097	1,110	1,130	769	845	863	890	956	978	896	921
Total Debt	862	881	896	553	623	667	711	755	798	701	724
Total Long-Term Debt	773	788	803	369	440	484	528	571	615	538	582
Net Debt	645	694	751	281	305	357	406	429	529	527	589
Capital Expenditures (CapEx)	0.80	0.57	0.24	0.27	0.57	0.16	0.07	0.06	0.18	0.94	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-88	-121	-67	-40	-42	-48	-49	-40	-0.55	-25	-1.74
Debt-free Net Working Capital (DFNWC)	130	66	78	232	276	263	256	286	269	149	132
Net Working Capital (NWC)	41	-27	-16	48	93	80	72	102	86	-14	-9.28
Net Nonoperating Expense (NNE)	14	15	12	12	9.73	10	12	13	35	15	6.07
Net Nonoperating Obligations (NNO)	645	694	751	280	304	357	405	428	526	525	587
Total Depreciation and Amortization (D&A)	58	58	42	36	37	37	39	41	41	45	41
Debt-free, Cash-free Net Working Capital to Revenue	-13.19%	-19.24%	-11.19%	-6.90%	-7.39%	-8.39%	-8.92%	-7.43%	-0.10%	-5.37%	-0.48%
Debt-free Net Working Capital to Revenue	19.57%	10.50%	13.00%	40.20%	48.71%	46.41%	46.80%	53.18%	51.23%	32.07%	36.60%
Net Working Capital to Revenue	6.15%	-4.32%	-2.61%	8.41%	16.37%	14.06%	13.26%	19.04%	16.31%	-2.96%	-2.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.08	$0.39	$0.29	$0.60	$0.86	$0.95	$0.61	$0.38	($0.51)	($0.21)	$0.01
Adjusted Weighted Average Basic Shares Outstanding	31.79M	32.27M	32.26M	32.43M	32.33M	33.74M	33.74M	34.62M	34.32M	33.83M	34.06M
Adjusted Diluted Earnings per Share	$0.07	$0.36	$0.27	$0.52	$0.71	$0.93	$0.53	$0.34	($0.51)	($0.21)	$0.01
Adjusted Weighted Average Diluted Shares Outstanding	32.84M	40.42M	40.16M	40.38M	41.44M	41.79M	42.06M	42.85M	34.32M	33.83M	34.57M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.14M	31.49M	32.25M	32.21M	32.72M	31.96M	32.61M	34.73M	34.59M	34.07M	33.57M
Normalized Net Operating Profit after Tax (NOPAT)	16	28	21	32	37	42	32	26	17	8.23	14
Normalized NOPAT Margin	9.10%	15.21%	13.10%	22.02%	25.83%	28.17%	23.60%	19.21%	11.91%	6.35%	11.28%
Pre Tax Income Margin	1.76%	9.49%	9.78%	20.03%	25.27%	31.19%	21.05%	13.13%	-12.13%	-6.01%	1.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.04	1.68	1.55	2.08	2.85	3.20	2.17	1.63	0.55	0.57	1.07
NOPAT to Interest Expense	0.81	1.22	0.93	1.40	2.16	2.19	1.55	1.19	0.38	0.40	0.34
EBIT Less CapEx to Interest Expense	1.00	1.66	1.53	2.07	2.82	3.19	2.16	1.63	0.54	0.53	1.07
NOPAT Less CapEx to Interest Expense	0.77	1.20	0.92	1.39	2.13	2.18	1.55	1.19	0.38	0.35	0.34
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	86.75%	67.72%	110.12%	80.39%	155.75%	639.32%	-126.00%	-47.90%	-56.25%	-90.48%

Frequently Asked Questions About Collegium Pharmaceutical's Financials

When does Collegium Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Collegium Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Collegium Pharmaceutical's net income changed over the last 10 years?

Collegium Pharmaceutical's net income appears to be on a downward trend, with a most recent value of $69.19 million in 2024, rising from $0.00 in 2014. The previous period was $48.16 million in 2023. Find out what analysts predict for Collegium Pharmaceutical in the coming months.

What is Collegium Pharmaceutical's operating income?

Collegium Pharmaceutical's total operating income in 2024 was $169.90 million, based on the following breakdown:

Total Gross Profit: $377.34 million
Total Operating Expenses: $207.45 million

How has Collegium Pharmaceutical revenue changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's total revenue changed from $0.00 in 2014 to $631.45 million in 2024, a change of 63,144,900,000.0%.

How much debt does Collegium Pharmaceutical have?

Collegium Pharmaceutical's total liabilities were at $1.43 billion at the end of 2024, a 51.4% increase from 2023, and a 8,178.5% increase since 2014.

How much cash does Collegium Pharmaceutical have?

In the past 10 years, Collegium Pharmaceutical's cash and equivalents has ranged from $1.63 million in 2014 to $238.95 million in 2023, and is currently $70.57 million as of their latest financial filing in 2024.

How has Collegium Pharmaceutical's book value per share changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's book value per share changed from -95.66 in 2014 to 7.10 in 2024, a change of -107.4%.

Related Companies

This page (NASDAQ:COLL) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Financials

Frequently Asked Questions About Collegium Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Financials

Annual Income Statements for Collegium Pharmaceutical

Quarterly Income Statements for Collegium Pharmaceutical

Annual Cash Flow Statements for Collegium Pharmaceutical

Quarterly Cash Flow Statements for Collegium Pharmaceutical

Annual Balance Sheets for Collegium Pharmaceutical

Quarterly Balance Sheets for Collegium Pharmaceutical

Annual Metrics And Ratios for Collegium Pharmaceutical

Quarterly Metrics And Ratios for Collegium Pharmaceutical

Frequently Asked Questions About Collegium Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools